Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Addressing Barriers Contributing to Disparities in CRC Screening in Underserved Populations

May 20th 2022

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

Dr. Oberstein on Remaining Challenges in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Dr. Oberstein on the CheckMate 9X8 Trial in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Dr. O'Malley on Racial and Economic Barriers to Screening in CRC

May 13th 2022

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

Superagonists Pull IL-15 Into Focus in Oncology Care

May 11th 2022

Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.

Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC

May 9th 2022

Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

European Commission Approves Pembrolizumab for Select MSI-H/dMMR Solid Tumors

April 29th 2022

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRC

April 19th 2022

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

Dr. Cusnir on the Most Effective Uses of Chemotherapy Treatment in CRC

April 19th 2022

Mike Cusnir, MD, discusses the most effective uses of chemotherapy in colorectal cancer.

Dr. Oberstein on the Utilization of CtDNA in Metastatic CRC

April 18th 2022

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

Dr. Hong on Comparing the Use of Sotorasib and Adagrasib in CRC

April 14th 2022

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

April 14th 2022

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.

Dr. Oberstein on the Current Treatment Landscape of CRC

April 13th 2022

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

Dr. Jeyarajah on Aggressive Treatment while Preserving Quality of Life in CRC

April 12th 2022

Rohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.

Dr. Kopetz on the BEACON CRC Study and Efficacy Response Analysis in mCRC

April 12th 2022

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

Patient Goals and Characteristics Play an Outsized Role in Determining First-Line Treatment for mCRC

April 6th 2022

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC

April 1st 2022

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.

Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022

March 24th 2022

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.

Temozolomide Followed by Low-Dose Ipilimumab/Nivolumab Shows Potential in MSS and MGMT-Silenced mCRC

March 23rd 2022

Temozolomide priming followed by the combination of low-dose ipilimumab and nivolumab may produce durable clinical benefit in microsatellite stable and MGMT-silenced metastatic colorectal cancer.

Regorafenib/Pembrolizumab Misses PFS End Point in MSS CRC, But Biomarker Analyses Are Ongoing

March 21st 2022

Afsaneh Barzi, MD, PhD, discusses the safety and efficacy of regorafenib in combination with pembrolizumab in patients with MSS colorectal cancer and describes potential next steps for further exploration of novel combinations in this population.